Executive Summary

BioSeeker's Research Unit has released a unique CD-ROM database compiled to enable your independent and unbiased analysis of different areas of leukemia therapeutics progress and pitfalls as well as competition and business opportunities. The information in the database has carefully been selected and structured to provide the most optimal and time saving platform to work from. The database contains extensive corporate, R&D, patent and business information. It includes extensive presentations of more than 60 selected companies activities in this field. In total, the database includes more than 5000 records from a multitude of information sources and thousands of related patents.

Generally, the database is structured into four sections:

R&D activities
Patents
Collaborations
Company profiles

The R&D information is structured into 11 searchable segments:

Investigator
Drug name
Combinatory drugs
Developmental stage
Indication
Sub-indication
Therapy given
Drug Effects
Mechanisms/Targets
General comments
Source of data

The collaboration information is structured into 5 searchable segments:

Collaborators
Product
Developmental stage
Type of collaboration
Type of terms
The database will help you in:

Tracking and describing cutting edge companies, therapies and new technologies Assessing the development status of competing drugs Allowing users to view comprehensive company pipelines. Rapid identification of partners & competitors Identify and structure most B2B collaborations and industry-academic alliances Laying down a comprehensive framework for further analysis of the field Producing presentations surrounding the development of cancer therapeutics Identifying emerging cancer products & key areas of pharmaceutical R&D

Some of the drugs included in the database:

AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999

Some of the companies included in the database:

Aventis, Antigenics, Biogen/ IDEC, Berlex Laboratories, Inc., Corixa Corporation, Celgene Corporation, Chiron, Cephalon Inc, Genentech, Exelixis Inc, Genta Incorporated, GlaxoSmithKline, ILEX Oncology Inc., Immuno-Designed Molecules, IDM, Immunex Corp, J&J PRD, Ligand Pharmaceuticals, Maxim Pharmaceuticals, Medarex, Merck, Millennium Pharma., Novartis, OSI Pharmaceuticals, Point Therapeutics, Protein Design Labs, Pfizer (Pharmacia), Pharmatech Oncology, Pharmasset, Inc., Pharmacyclics, Schering-Plough, Supergen, Roche, Schering AG, Schering Corporation, Shire Pharmaceuticals, Seragen, Vion Pharmaceuticals, Inc.

Related Reports:
Prostate Cancer Drug Discoveries: What the Future Holds
Competitor Analysis: TGF-R Agonists and Antagonists
CDK Inhibitors Patent Landscape 2009
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Blood, Organ & Ambulatory Health Services in the US - Industry Risk Rating Report
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Top 20 Cancer Therapy Brands Forecast
Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
Strategic Analysis of the Bladder Cancer Therapeutics